



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,616	12/19/2000	Anthony Eamon Storey	PA-9816	1582
36335	7590	01/18/2006	EXAMINER	
AMERSHAM HEALTH IP DEPARTMENT 101 CARNEGIE CENTER PRINCETON, NJ 08540-6231			AUDET, MAURY A	
			ART UNIT	PAPER NUMBER
			1654	

DATE MAILED: 01/18/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Supplemental  
Notice of Allowability**

Application No.

09/674,616

Examiner

Maury Audet

Applicant(s)

STOREY ET AL.

Art Unit

1654

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 02/07/2005.
2. ☒ The allowed claim(s) is/are 22-31.
3. ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some\* c) ☐ None of the:
- ☒ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |   |   |
|---|---|
| 1. <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)           |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                | 6. <input type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date _____ |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),<br>Paper No./Mail Date _____ | 7. <input checked="" type="checkbox"/> Examiner's Amendment/Comment                   |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material          | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance             |
|   | 9. <input type="checkbox"/> Other _____   |

**SUPPLEMENTAL EXAMINER'S AMENDMENT**


An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Li Cai, Attorney for Applicant, on April 27, 2005 and January 09, 2006.

**IN THE CLAIMS**

Please replace claim 20 in its entirety, with the following new claim 31:

31. A compound of formula:



where :

X is C=O or CR<sub>2</sub>;

n is an integer of value 1 to 6;

Y is R<sup>1</sup>R<sup>2</sup>CR-where one of R<sup>1</sup> and R<sup>2</sup> is -NH(B)<sub>p</sub>Z<sup>1</sup> and the other

is -CO(B)<sub>q</sub>Z<sup>2</sup> where

p and q are integers of value 0 to 30, and

each B is independently chosen from Q or an amino acid residue,

where Q is a cyclic peptide;

Art Unit: 1654

$Z^1$  and  $Z^2$  are metal complexing agents (L) or other protecting groups,  
which are

biocompatible groups which inhibit or suppress *in vivo* metabolism of the  
peptide;

J and each R are independently chosen from H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkenyl, C<sub>1-4</sub>  
alkynyl, C<sub>1-4</sub> alkoxyalkyl or C<sub>1-4</sub> hydroxyalkyl;

with the proviso that:

- (i) when X is CR<sub>2</sub>, then  $Z^2$  is a metal complexing agent (L);
- (ii) at least one of R<sup>1</sup> and R<sup>2</sup> bears at least one detectable moiety suitable for  
diagnostic imaging of the human body;
- (iii) R<sup>1</sup> and R<sup>2</sup> include one or more of the peptide sequence consisting of  
NQE QVSPYTLLKG (SEQ ID NO: 2), which is a peptide fragment of  $\alpha_2$ -antiplasmin.

In claims 22, 24, 29, and 30, at line 1, the number "20" has been changed  
to --31--.

Claim 20-21 have been cancelled without prejudice.

Art Unit: 1654

**IN THE SPECIFICATION**

Please insert the following paragraph, in it's entirety, at the bottom of page 14 of the specification:

**DETAILED DESCRIPTION OF THE DRAWINGS**

Fig. 1: Imaging of clots induced in a rat model with  $^{99m}\text{Tc}$ -Compound 5.

Images shown were acquired at 15 min p.i., 30 min p.i., 60 min p.i., and 180 min p.i.

Fig. 2: Imaging of clots induced in a rat model with  $^{99m}\text{Tc}$ -Compound 5:  
detailed image at 180 min p.i.

***Conclusion***


Claims 22-31 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 571-272-0960. The examiner can normally be reached from 7:00 AM – 5:30 PM, off Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campbell can be reached at 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

MA, 01/10/2005



BRUCE R. CAMPBELL, PH.D  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600